

BC Cancer ST Program Updates for March 3, 2025


AFFECTED APPLICATION(S)	PowerChart: Oncology/Hematology Regimens and PowerPlans
AFFECTED AREA(S)	BC Cancer Sites / VCH Oncology Sites (Oncologists, Oncology Pharmacy, and Oncology Nursing Staff)
NET NEW, OR UPDATE TO EXISTING BUILD	Update to Existing Build

What has Changed?

Any changes released that affect Oncology Regimens and PowerPlans/Cycles for the **BC Cancer Systemic Therapy (ST) Program** will be communicated monthly via Special Bulletin. These notification changes are important for Nursing staff, Pharmacy, and Providers to be aware of for their patients' care.

For Providers:

- **For PowerPlans that are versioned:** If your patient has already been started on a Regimen, when you order the next cycle PowerPlan, a pop-up window will appear to indicate a new version is required.
 - Click **Yes** to accept the new version
 - **Do not** use the Copy Forward functionality to ensure that the updates apply



- **IMPORTANT:** Any change from the standard treatment regimen (dose modification, addition of pre-med, etc.) in the previous cycle will need to be manually added to the cycle that is being ordered with the new version (see additional documentation regarding versioning)

Please see this month's changes below:

Protocols: LUAJNP

Cycles/PowerPlans: ONCP LU LUAJNP

Changes:

Chemotherapy Phase:

- Removed Day 15 Treatment Day

ONCP LU LUAJNP - Cycle 1, Chemotherapy (Day 1, 8) (Future Pending) *Est. 20-Feb-2025 08:00 PST - 21 Days

Component	Day 1	Day 8
	Future Pending *Est. 20-Feb-2025 08:...	Future Pending *Est. 27-Feb-2025 08:...
Link to Protocol: Adjuvant CISplatin and Vinorelbine Following Resection of Non-Small Cell Lung Cancer		
Revised: 1 Mar 2025		
Pre-Chemo Metrics		
May proceed with treatment on Day 1 if:		
Neutrophils Greater Than or Equal to $1.5 \times 10^9/L$ within 24 hours		
Platelet Count Greater Than or Equal to $100 \times 10^9/L$ within 24 hours		
Creatinine Clearance Greater Than or Equal to 60 mL/min within 24 hours		
May proceed with treatment on Day 8 and Day 15 if:		
Neutrophils Greater Than or Equal to $1.5 \times 10^9/L$ within 24 hours		

- Updated CISplatin dose to 75 mg/m2

<input checked="" type="checkbox"/> CISplatin-KCL 20 mmol-magnesium sulfate 1g-mannitol 30g in NS 500 mL 75 mg/m2, IV, once oncology, administer over: 60 minute, drug form: bag Day 1	Planned 0 min
--	------------------

- Revised vinorelbine to be given on Days 1 and 8

ONCP LU LUAJNP - Cycle 1, Chemotherapy (Day 1, 8) (Future Pending) *Est. 20-Feb-2025 08:00 PST - 21 Days

Component	Day 1	Day 8
	Future Pending *Est. 20-Feb-2025 08:...	Future Pending *Est. 27-Feb-2025 08:...
vinorelbine (vinorelbine - oncology)	Planned +60 min	Planned 0 min
30 mg/m2, IV, once oncology, administer over: 6 minute, drug form: bag Flush vein with 75 to 125 mL sodium chloride 0.9% following infusion of vinorelbine.	Planned	Planned

Labs Phase:

- Removed labs on Day 15

Component	Day 8	Day 22
CBC and Differential Blood, once, Order for future visit	Future Pending *Est. 26-Feb-2025 08:...	Future Pending *Est. 12-Mar-2025 08:...
Creatinine and Estimated GFR Blood, once, Order for future visit	Planned	Planned
If clinically indicated:		
Bilirubin Total Blood, once, Order for future visit		Planned

Scheduling Phase:

- Removed Scheduling order “Infusion Chemotherapy Visit” for Day 15

Component	Status	Dose ...	Details
Infusion Chemotherapy Visit			Within 2 Weeks, Cycle 1: Chair time 195 minutes; Nurse time 70 minutes, Chair Time: 180 minutes, Nur Day 1
Infusion Chemotherapy Visit			Within 2 Weeks, Chair Time: 60 minutes, Nurse Time: 55 minutes, ONCP LU LUAJNP Day 8
Follow Up - Clinic - Oncology On Treatment			Physician Specialty: Medical Oncology, Tumor Group: Lung

Versioning:

Jira: CST-305436

PowerPlan: LUAVPIPNI

Cycles/PowerPlans: ONCP LU LUAVPIPNI CARBOplatin Option Cycle 1, ONCP LU LUAVPIPNI CARBOplatin Option Cycle 2, ONCP LU LUAVPIPNI CISplatin Option Cycle 1, ONCP LU LUAVPIPNI CISplatin Option Cycle 2, ONCP LU LUAVPIPNI Cycles 3+

Changes:

Chemotherapy phase:

Updated CDS Notes from “Order Weekly Nursing Assessment” to “Order Weekly Nursing Assessment (Optional)”

Procedural/Schedulable Orders
Order Weekly Nursing Assessment (Optional)

- Added hypersensitivity tray to ONCP LU LUAVPIPNI Cycles 3+ only:

ONCP LU LUAVPIPNI Cycles 3+ - Cycle 3, Chemotherapy (Day 1, 22) (Future Pending) *Est. 13-Feb-2025 08:00 PST - 42 D			Day 1	Day 22
🔍	📄	Component	Future Pending	Future Pending
			*Est. 13-Feb-2025 08:...	*Est. 06-Mar-2025 08:...
			Actions	Actions
🔔 Have Hypersensitivity Reaction Tray and Protocol Available. Contact provider for additional orders				
<input checked="" type="checkbox"/>		🔔 diphenhydrAMINE 50 mg, IV, once oncology, PRN other (see comment), drug f... For hypersensitivity reaction	Planned	Planned
<input checked="" type="checkbox"/>		🔔 hydrocortisone 100 mg, IV, once oncology, PRN other (see comment), drug ... For hypersensitivity reaction	Planned	Planned
<input checked="" type="checkbox"/>		🔔 epinephrine (epinephrine 1 mg/mL inj) 0.5 mg, IM, q5min, PRN anaphylaxis, order duration: 3 doses...	Planned	Planned
<input checked="" type="checkbox"/>		🔔 salbutamol 5 mg, nebulized, q20min, PRN shortness of breath or wheezi...	Planned	Planned

Labs phase in CARBOplatin and CISplatin PowerPlans:

- Removed Day 8 and Day 15 CBC and Differential

🔍	📄	Component	Day 1 Future Pending *Est. 07-Mar-2025 08:...
<input checked="" type="checkbox"/>		🔔 CBC and Differential Blood, once, Order for future visit	Planned
<input checked="" type="checkbox"/>		🔔 Creatinine and Estimated GFR Blood, once, Order for future visit	Planned
<input checked="" type="checkbox"/>		🔔 Alanine Aminotransferase Blood, once, Order for future visit	Planned
<input checked="" type="checkbox"/>		🔔 Alkaline Phosphatase Blood, once, Order for future visit	Planned
<input checked="" type="checkbox"/>		🔔 Bilirubin Total Blood, once, Order for future visit	Planned
<input checked="" type="checkbox"/>		🔔 Lactate Dehydrogenase Blood, once, Order for future visit	Planned
<input checked="" type="checkbox"/>		🔔 Sodium and Potassium Panel (Electrolytes Panel Outpat... Blood, once, Order for future visit	Planned
<input checked="" type="checkbox"/>		🔔 Thyroid Stimulating Hormone Blood, once, Order for future visit	Planned
<input checked="" type="checkbox"/>		🔔 Creatine Kinase Blood, once, Order for future visit	Planned
<input checked="" type="checkbox"/>		🔔 Glucose Random Blood, once, Order for future visit	Planned
<input type="checkbox"/>		🔔 If clinically indicated: 🔔 Free T3 Level (Free T3 Level Outpatient) Blood, Thyroid Cancer – Thyrotoxicosis, once, Order for futu...	
<input type="checkbox"/>		🔔 Free T4 Level (Free T4 Level Outpatient) Blood, Thyroid Cancer – Thyrotoxicosis, once, Order for futu...	
<input type="checkbox"/>		🔔 Cortisol Morning Blood, once, Order for future visit	
<input type="checkbox"/>		🔔 Adrenocorticotropic Hormone (ACTH) Level (ACTH Lev... Blood, once, Order for future visit	
<input type="checkbox"/>		🔔 Testosterone Level Blood, once, Order for future visit	
<input type="checkbox"/>		🔔 Estradiol Level Blood, once, Order for future visit	

Versioning: Yes

Jira: CST-303762

Protocols: LUNETEV

Cycles/PowerPlans: All Associated PowerPlans

Changes:

In the Pretreatment Plan:

- Added required Albumin Level and INR
- Added optional Hemoglobin A1C, Total Protein, Gamma Glutamyl Transferase, and Hepatitis B Surface Antibody
- Updated CDS yellow note to: *“If HBsAg or HBcoreAb positive, start antiviral prophylaxis as per current guidelines”*

ONCP LU LUNETEV Pretreatment Plan, Baseline Labs (Day 1) (Future Pending) *Est. 21-Feb-2025 08:43		
	Component	Day 1 Future Pending *Est. 21-Feb-2025 08:43 Actions
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/> Lactate Dehydrogenase Blood, once, Order for future visit	Planned
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/> Bilirubin Total Blood, once, Order for future visit	Planned
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/> Alkaline Phosphatase Blood, once, Order for future visit	Planned
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/> Cholesterol Level Blood, once, Order for future visit	Planned
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/> Triglyceride Blood, once, Order for future visit	Planned
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/> Albumin Level Blood, once, Order for future visit	Planned
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/> INR Blood, once, Order for future visit	Planned
	<input checked="" type="checkbox"/> If clinically indicated:	
<input type="checkbox"/>	<input checked="" type="checkbox"/> Gamma Glutamyl Transferase Blood, once, Order for future visit	
<input type="checkbox"/>	<input checked="" type="checkbox"/> Protein Level (Total Protein Level) Blood, once, Order for future visit	
<input type="checkbox"/>	<input checked="" type="checkbox"/> Hemoglobin A1C Blood, once, Order for future visit	
<input type="checkbox"/>	<input checked="" type="checkbox"/> Hepatitis B Surface Antigen BCCDC Blood, once, Order for future visit	
<input type="checkbox"/>	<input checked="" type="checkbox"/> Hepatitis B Core Antibody Total BCCDC Blood, once, Order for future visit	
<input type="checkbox"/>	<input checked="" type="checkbox"/> Hepatitis B Surface Antibody BCCDC Blood, once, Order for future visit	
	<input checked="" type="checkbox"/> If HBsAg or HBcoreAb positive, start antiviral prophylaxis as per current guidelines	

In the Treatment Powerplan:

- Updated labs so only CBC and Differential is required and all other labs are optional
- Added optional INR, Magnesium Level, Creatine Kinase, Hemoglobin A1C, Urinalysis Macroscopic (dipstick), Protein Urine 24 Hour, Collection Information Urine 24 Hour, Creatinine Urine 24 Hour (and all associated notes)

ONCP LU LUNETEV (PO) - Cycle 1, Next Cycle Labs (Day 1) (Future Pending) *Est. 20-Mar-2025 10:00		
	Component	Day 1 Future Pending *Est. 20-Mar-2025 10:00 Actions
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/> CBC and Differential Blood, once, Order for future visit	Planned
	<input checked="" type="checkbox"/> If clinically indicated:	
<input type="checkbox"/>	<input checked="" type="checkbox"/> Creatinine and Estimated GFR Blood, once, Order for future visit	
<input type="checkbox"/>	<input checked="" type="checkbox"/> Bilirubin Total Blood, once, Order for future visit	
<input type="checkbox"/>	<input checked="" type="checkbox"/> Alanine Aminotransferase Blood, once, Order for future visit	
<input type="checkbox"/>	<input checked="" type="checkbox"/> Alkaline Phosphatase Blood, once, Order for future visit	
<input type="checkbox"/>	<input checked="" type="checkbox"/> INR Blood, once, Order for future visit	
<input type="checkbox"/>	<input checked="" type="checkbox"/> Magnesium Level Blood, once, Order for future visit	
<input type="checkbox"/>	<input checked="" type="checkbox"/> Creatine Kinase Blood, once, Order for future visit	
<input type="checkbox"/>	<input checked="" type="checkbox"/> Hemoglobin A1C Blood, once, Order for future visit	
<input type="checkbox"/>	<input checked="" type="checkbox"/> Urinalysis Macroscopic (dipstick) Urine, once, Order for future visit	
	<input checked="" type="checkbox"/> If laboratory urinalysis for protein is greater than or equal to 1 g/L, then a 24 hr urine for total protein must be done within 3 days prior to the next cycle	
<input type="checkbox"/>	<input checked="" type="checkbox"/> Protein Urine 24 Hour Urine, once, Order for future visit	
	<input checked="" type="checkbox"/> 'Collection Information Urine 24 Hour' and 'Creatinine Urine 24 Hour' are required tests for 24 hour urine tests	
<input type="checkbox"/>	<input checked="" type="checkbox"/> Collection Information Urine 24 Hour Urine, once, Order for future visit	
<input type="checkbox"/>	<input checked="" type="checkbox"/> Creatinine Urine 24 Hour Urine, once, Order for future visit	

Versioning: Yes

Jira: CST-305678

Protocols: ULYEPCOR

Cycles/PowerPlans: All Associated PowerPlans

Changes:

For all Powerplans:

- Added Optional Immunoglobulin panel (IgA, IgG, IgM)

ONCP LY ULYEPCOR Pretreatment Plan, Baseline Labs (Day 1) (Future Pending) *Est. 21-Feb-2025

Component	Day 1 Future Pending *Est. 21-Feb-2025 08:00 PST - 28 Days
<input checked="" type="checkbox"/> If HBsAg or HBcAb positive, follow hepatitis B prophylaxis as per SCHBV protocol	
<input checked="" type="checkbox"/> If clinically indicated:	
<input checked="" type="checkbox"/> Creatinine and Estimated GFR Blood, once, Order for future visit	
<input checked="" type="checkbox"/> Sodium and Potassium Panel (Electrolytes Panel Outpat... Blood, once, Order for future visit	
<input checked="" type="checkbox"/> Urea Level Blood, once, Order for future visit	
<input checked="" type="checkbox"/> Uric Acid Blood, once, Order for future visit	
<input checked="" type="checkbox"/> Bilirubin Total Blood, once, Order for future visit	
<input checked="" type="checkbox"/> Alanine Aminotransferase Blood, once, Order for future visit	
<input checked="" type="checkbox"/> Alkaline Phosphatase Blood, once, Order for future visit	
<input checked="" type="checkbox"/> Phosphate Level Blood, once, Order for future visit	
<input checked="" type="checkbox"/> Calcium Level Blood, once, Order for future visit	
<input checked="" type="checkbox"/> Albumin Level Blood, once, Order for future visit	
<input checked="" type="checkbox"/> Lactate Dehydrogenase Blood, once, Order for future visit	
<input checked="" type="checkbox"/> Glucose Random Blood, once, Order for future visit	
<input checked="" type="checkbox"/> Immunoglobulin Panel (IgA, IgG, IgM) Blood, once, Order for future visit	

For Treatment Powerplans:

- Added optional HBV Viral Load for every 3 months

ONCP LY ULYEPCOR Cycle 1 - Cycle 1, Labs (Day 8, 15, 22, 29) (Future Pending) *Est. 27-Feb-2025 08:00 PST - 28 Days

Component	Day 8 Future Pending *Est. 27-Feb-2025 08:00 PST - 28 Days	Day 15 Future Pending *Est. 06-Mar-2025 08:00 PST - 28 Days	Day 22 Future Pending *Est. 13-Mar-2025 08:00 PST - 28 Days	Day 29 Future Pending *Est. 20-Mar-2025 08:00 PST - 28 Days
<input checked="" type="checkbox"/> If clinically indicated:				
<input checked="" type="checkbox"/> Sodium and Potassium Panel (Electrolytes Panel Outpat... Blood, once, Order for future visit				
<input checked="" type="checkbox"/> Creatinine and Estimated GFR Blood, once, Order for future visit				
<input checked="" type="checkbox"/> Uric Acid Blood, once, Order for future visit				
<input checked="" type="checkbox"/> Calcium Level Blood, once, Order for future visit				
<input checked="" type="checkbox"/> Magnesium Level Blood, once, Order for future visit				
<input checked="" type="checkbox"/> Phosphate Level Blood, once, Order for future visit				
<input checked="" type="checkbox"/> Glucose Random Blood, once, Order for future visit				
<input checked="" type="checkbox"/> Albumin Level Blood, once, Order for future visit				
<input checked="" type="checkbox"/> Bilirubin Total Blood, once, Order for future visit				
<input checked="" type="checkbox"/> Alanine Aminotransferase Blood, once, Order for future visit				
<input checked="" type="checkbox"/> Alkaline Phosphatase Blood, once, Order for future visit				
<input checked="" type="checkbox"/> Lactate Dehydrogenase Blood, once, Order for future visit				
<input checked="" type="checkbox"/> Immunoglobulin Panel (IgA, IgG, IgM) Blood, once, Order for future visit				
<input checked="" type="checkbox"/> If clinically indicated, every 3 months				
<input checked="" type="checkbox"/> Hepatitis B Viral Load (Rx monitoring) (HBV Viral Load) Blood, once, Order for future visit				

Versioning: Yes

Jira: CST-302330

Protocols: LUAJNIVPP, LUAJPP, LUAVPEM, LUAVPMTN, LUAVPP, LUAVPPPMB, LUMMPP

Cycles/PowerPlans: All Associated PowerPlans and Regimens

Changes:

For all protocols:

- Removed Cycles 1 and 2 Powerplans
- Renamed and updated Cycles 3+ Powerplan to contain no cycle information
- Updated Regimens to include only the single Powerplan

ONC LU LUAJPP (Pending)
 Hide additional details
 Regimen description: Adjuvant Cisplatin and Pemetrexed Following Resection of Non-Small Cell Lung Cancer

+ Add Document Response View Responses

ONC LU LUAJPP Pretreatment Plan *Est. Start Date: 01-Mar-2025 **Skip**

Start

ONC LU LUAJPP - Cycle 1	*Est. Start Date: 01-Mar-2025
ONC LU LUAJPP - Cycle 2	*Est. Start Date: 22-Mar-2025
ONC LU LUAJPP - Cycle 3	*Est. Start Date: 12-Apr-2025
ONC LU LUAJPP - Cycle 4	*Est. Start Date: 03-May-2025

Extend

Versioning: Yes

Jira: CST-303761

Protocols: LYEPOCHR

Cycles/PowerPlans: All Associated treatment PowerPlans

Changes:

ONCP LY LYEPOCHR (Outpatient)

Chemotherapy Phase:

For etoposide-DOXOrubicin-VinCRistine in NS (non-DEHP) 500 mL orders to add into the order comment: 'If total given volume on CADD pump is equal to volume indicated on medication label, may disconnect medication bag with volume remaining'

Details for etoposide additive 50 mg/m2 + DOXOrubicin additive 10 mg/m2 + vinCRistine additive 115 mg + sodium chloride 0.9% (NS) (non-DEHP) IV diluent 525 mL

Details Ingredient Details

Ingredients	Dose	Rate	Infuse Over	Frequency	Duration
etoposide additive	50 mg/m2	21.88 mL/h	24 hour	once oncology	
DOXOrubicin additive	10 mg/m2				
vinCRistine additive	115 mg				
sodium chloride 0.9% (NS) (non-DEHP) IV diluent	525 mL				
Total Volume		525 mL			

Order comments
 Dose Level Minus 2. Use non-DEHP tubing with 0.2 micron in-line filter. If total given volume on CADD pump is equal to volume indicated on medication label, may disconnect medication bag with volume remaining. Days 1 to 4
 Target Dose: vinCRistine additive 50 mg/m2 24-Feb-2025 15:27:35

Prescriptions Phase:

Deselected the mesna orders, they should be optional

Add yellow CDS note to the top that says "Ensure appropriate supportive care medications are prescribed e.g. PJP prophylaxis, PPI, G-CSF"

Prescriptions (Inpatient Only Use) Phase:

Added yellow CDS note to the top that says 'Ensure appropriate supportive care medications are prescribed e.g. PJP prophylaxis, PPI, G-CSF'

Labs Phase:

- Have mandatory CBC, INR and PPT on Day 22 only
- Create yellow CDS note 'If receiving intrathecal methotrexate, on Day 4:' and add another optional CBC, INR and PTT underneath

ONCP LYEPOCHR (Outpatient) - Cycle 2, Labs (Days 4, 22) (Future Pending) *Est. 25-Feb-2025 08:00 PST - 25 Days		Days 4 Future Pending *Est. 25-Feb-2025 08:...	Days 22 Future Pending *Est. 15-Mar-2025 08:...
Component		Actions	Actions
<input checked="" type="checkbox"/> CBC and Differential Blood, once, Order for future visit			Planned
<input checked="" type="checkbox"/> INR Blood, once, Order for future visit			Planned
<input checked="" type="checkbox"/> PTT Blood, once, Order for future visit			Planned
If receiving intrathecal methotrexate, on Day 4:			
<input type="checkbox"/> CBC and Differential Blood, once, Order for future visit			
<input type="checkbox"/> INR Blood, once, Order for future visit			
<input type="checkbox"/> PTT Blood, once, Order for future visit			
If clinically indicated:			
<input type="checkbox"/> Bilirubin Total Blood, once, Order for future visit			
<input type="checkbox"/> Alanine Aminotransferase Blood, once, Order for future visit			
<input type="checkbox"/> Urinalysis Macroscopic (dipstick) Urine, once, Order for future visit			
<input type="checkbox"/> Creatinine and Estimated GFR Blood, once, Order for future visit			
<input type="checkbox"/> Alkaline Phosphatase Blood, once, Order for future visit			
<input type="checkbox"/> Lactate Dehydrogenase Blood, once, Order for future visit			
If clinically indicated every 3 months:			
<input type="checkbox"/> Hepatitis B Viral Load (Rx monitoring) (HBV Viral Load) Blood, once, Order for future visit			

Versioning: Yes

Jira: CST-305459

Protocols: BRAVEVEX

Cycles/PowerPlans: All Associated PowerPlans

Changes:

ONCP BR BRAVEVEX Pretreatment plan:

- Move albumin from 'if clinically indicated' to mandatory

ONCP BR BRAVEVEX Pretreatment Plan, Baseline Labs (Day 1) (Future Pending) *Est. 25-Feb-2025 08:00 PST - 1 Days			Day 1
<input type="checkbox"/>	<input type="checkbox"/>	Component	Future Pending *Est. 25-Feb-2025 08:...
			Actions
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	CBC and Differential Blood, once, Order for future visit	Planned
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	INR Blood, once, Order for future visit	Planned
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	Creatinine and Estimated GFR Blood, once, Order for future visit	Planned
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	Urea Level Blood, once, Order for future visit	Planned
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	Glucose Random Blood, once, Order for future visit	Planned
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	Hemoglobin A1C (HbA1c) Blood, once, Order for future visit	Planned
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	Bilirubin Total Blood, once, Order for future visit	Planned
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	Albumin Level Blood, once, Order for future visit	Planned
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	Alanine Aminotransferase Blood, once, Order for future visit	Planned
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	Alkaline Phosphatase Blood, once, Order for future visit	Planned
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	Lactate Dehydrogenase Blood, once, Order for future visit	Planned
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	Sodium and Potassium Panel (Electrolytes Panel Outpatient (Na, K)) Blood, once, Order for future visit	Planned
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	Calcium Level Blood, once, Order for future visit	Planned
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	Phosphate Level (Phosphorus Level) Blood, once, Order for future visit	Planned
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	Cholesterol Level Blood, once, Order for future visit	Planned
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	Triglyceride Blood, once, Order for future visit	Planned

- Update Hep B yellow CDS note to 'If HbsAg or HBcoreAb positive, start antiviral prophylaxis as per current guidelines'

<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	If HbsAg or HBcoreAb positive, start antiviral prophylaxis as per current guidelines	
<input type="checkbox"/>	<input checked="" type="checkbox"/>	Protein Level (Total Protein Level) Blood, once, Order for future visit	
<input type="checkbox"/>	<input checked="" type="checkbox"/>	Gamma Glutamyl Transferase Blood, once, Order for future visit	

ONCP BR BRAVEVEX (PO) Powerplan – **Next Cycle Labs** phase:

- Update 'Prior to Cycle 2' yellow CDS note to say 'Prior to Cycle 2, then prior to each visit
- Have a mandatory CBC and Diff under the heading and remove all the other labs.
- Remove 'Prior to each return to clinic' section

ONCP BR BRAVEVEX (PO) - Cycle 1, Next Cycle Labs (Day 1) (Future Pending) *Est. 24-Mar-2025 15:25 PDT - 1 Days			Day 1
<input type="checkbox"/>	<input type="checkbox"/>	Component	Future Pending *Est. 24-Mar-2025 15:...
			Actions
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	Prior to Cycle 2, then prior to each visit:	
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	CBC and Differential Blood, once, Order for future visit	Planned

- Add 'if clinically indicated': INR, HbA1C, magnesium, calcium, phosphate, creatine kinase, urinalysis, 24-hour urine protein
- Remove hepatitis B optional labs

If clinically indicated:		
<input type="checkbox"/>	<input checked="" type="checkbox"/> INR Blood, once, Order for future visit	
<input type="checkbox"/>	<input checked="" type="checkbox"/> Protein Level (Total Protein Level) Blood, once, Order for future visit	
<input type="checkbox"/>	<input checked="" type="checkbox"/> Albumin Level Blood, once, Order for future visit	
<input type="checkbox"/>	<input checked="" type="checkbox"/> Bilirubin Total Blood, once, Order for future visit	
<input type="checkbox"/>	<input checked="" type="checkbox"/> Gamma Glutamyl Transferase Blood, once, Order for future visit	
<input type="checkbox"/>	<input checked="" type="checkbox"/> Alkaline Phosphatase Blood, once, Order for future visit	
<input type="checkbox"/>	<input checked="" type="checkbox"/> Alanine Aminotransferase Blood, once, Order for future visit	
<input type="checkbox"/>	<input checked="" type="checkbox"/> Lactate Dehydrogenase Blood, once, Order for future visit	
<input type="checkbox"/>	<input checked="" type="checkbox"/> Urea Level Blood, once, Order for future visit	
<input type="checkbox"/>	<input checked="" type="checkbox"/> Creatinine and Estimated GFR Blood, once, Order for future visit	
<input type="checkbox"/>	<input checked="" type="checkbox"/> Glucose Random Blood, once, Order for future visit	
<input type="checkbox"/>	<input checked="" type="checkbox"/> Hemoglobin A1C (HbA1c) Blood, once, Order for future visit	
<input type="checkbox"/>	<input checked="" type="checkbox"/> Cholesterol Level Blood, once, Order for future visit	
<input type="checkbox"/>	<input checked="" type="checkbox"/> Triglyceride Blood, once, Order for future visit	
<input type="checkbox"/>	<input checked="" type="checkbox"/> Sodium and Potassium Panel (Electrolytes Panel Outpatient (Na, K)) Blood, once, Order for future visit	
<input type="checkbox"/>	<input checked="" type="checkbox"/> Magnesium Level Blood, once, Order for future visit	
<input type="checkbox"/>	<input checked="" type="checkbox"/> Calcium Level Blood, once, Order for future visit	
<input type="checkbox"/>	<input checked="" type="checkbox"/> Phosphate Level (Phosphorus Level) Blood, once, Order for future visit	
<input type="checkbox"/>	<input checked="" type="checkbox"/> Creatine Kinase Blood, once, Order for future visit	
<input type="checkbox"/>	<input checked="" type="checkbox"/> Urinalysis Macroscopic (dipstick) Urine, once, Order for future visit	
	<input checked="" type="checkbox"/> If laboratory urinalysis for protein is greater than or equal to 1 g/L or dipstick urinalysis proteinuria 2+ or 3+, then a 24 hr urine for total protein must be done within 3 days prior to the next cycle	
<input type="checkbox"/>	<input checked="" type="checkbox"/> Protein Urine 24 Hour Urine, once, Order for future visit	

Versioning: Yes

Jira: CST-305458


Protocols: LYGDPO

Cycles/PowerPlans:

- ONCP LY LYGDPO Pretreatment Plan
- ONCP LY LYGDPO CARBOplatin Option Induction Cycle 1
- ONCP LY LYGDPO CARBOplatin Option Induction Cycles 2 to 6
- ONCP LY LYGDPO CISplatin Option Induction Cycle 1
- ONCP LY LYGDPO CISplatin Option Induction Cycles 2 to 6
- ONCP LY LYGDPO CISplatin Split Dosing Option Induction Cycle 1
- ONCP LY LYGDPO CISplatin Split Dosing Option Induction Cycles 2 to 6
- ONCP LY LYGDPO Maintenance Cycles 7 to 18

ONCP LY LYGDPO Pretreatment Plan:


- Updated Yellow CDS note to: *"If HBsAg or HBcoreAb positive, start hepatitis B prophylaxis as per SCHBV protocol"*

 If HBsAg or HBcoreAb positive, start hepatitis B prophylaxis as per SCHBV protocol


ONCP LY LYGDPO Induction Cycle 1 (all options):

• **Chemotherapy phase:**

- CDS yellow note updated to: *'Give IV dexamethasone prior to oBINutuzumab infusion if reaction to previous oBINutuzumab was Grade 3, or lymphocyte counts greater than $25 \times 10^9/L$ before Cycle 1 Day 1':*

 Give IV dexamethasone prior to oBINutuzumab infusion if reaction to previous oBINutuzumab was Grade 3, or lymphocyte counts greater than $25 \times 10^9/L$ before Cycle 1 Day 1:

- Dexamethasone IV: removed administer over time

 dexamethasone
20 mg, IV, once oncology, drug form: inj
60 minutes prior to oBINutuzumab. Day 2

- All CDS yellow notes and orders for repeat medications to be given with oBINutuzumab infusion if exceeding 4 hours removed including: Dexamethasone, Acetaminophen PRN range dose, diphenhydramine
- Removed turquoise Clinical Decision Support note for vital signs and monitoring for oBINutuzumab
- Removed turquoise Clinical Decision Support note "Days 8 and 15: Vital signs prior to start of infusion, at every increment of infusion rate, and as clinically indicated post infusion"
- Order comments for oBINutuzumab Day 2 updated

Details for oBINutuzumab (oBINutuzumab - oncology)

Details Order Comments

Order comments

Start infusion at 50 mg/h; after 30 minutes, increase by 50 mg/h every 30 minutes until rate = 400 mg/h unless toxicity occurs. Refer to protocol appendix for oBINutuzumab infusion rate titration table. For first dose, constant visual observation during dose increases and for 30 minutes after infusion completed. Vital signs not required unless symptomatic.

If flushing, dyspnea, rigors, rash, pruritus, vomiting, chest pain, any other new acute discomfort or exacerbation of any existing symptoms occur, stop infusion and page physician. Day 2

- Order comments for oBINutuzumab Days 8 and 15 updated

Details for oBINutuzumab (oBINutuzumab - oncology)

Details Order Comments

Order comments

If no infusion reaction or only Grade 1 infusion reaction in the previous infusion and final infusion rate 100 mg/h or faster: Start infusion at 100 mg/h for 30 minutes; if tolerated, may escalate rate in increments of 100 mg/h every 30 minutes until rate = 400 mg/h. Refer to protocol appendix for oBINutuzumab infusion rate titration table. Days 8 and 15

- **Next cycle labs phase:**
 - Added unselected ALT (in addition to HBV Viral load)

If clinically indicated:

- Alanine Aminotransferase
Blood, once, Order for future visit
- Hepatitis B Viral Load (Rx monitoring)
Blood, once, Order for future visit

- **Scheduling phase:**
 - Updated nurse and chair times for Infusion Chemotherapy Visit Day 2, 8, and 15

<input checked="" type="checkbox"/>	Infusion Chemotherapy Visit	Within 2 Weeks, Chair Time: 360 Minutes, Nurse Time: 60 minutes, DNCP LY LYGDPPO CARBOplatin Option Induction Cycle 1 Day 2
<input checked="" type="checkbox"/>	Infusion Chemotherapy Visit	Within 2 Weeks, Chair Time: 300 minutes, Nurse Time: 45 minutes, DNCP LY LYGDPPO CARBOplatin Option Induction Cycle 1 Day 8
<input checked="" type="checkbox"/>	Infusion Chemotherapy Visit	Within 2 Weeks, Chair Time: 255 minutes, Nurse Time: 45 minutes, DNCP LY LYGDPPO CARBOplatin Option Induction Cycle 1 Day 15

ONCP LY LYGDPPO Induction Cycles 2 to 6 (all options):

- **Chemotherapy phase:**
 - Updated Clinical Decision Support yellow note to: *"If dexamethasone IV has been given the same day for the oBINutuzumab premedication, then omit dexamethasone PO"*

If dexamethasone IV has been given the same day for the oBINutuzumab premedication, then omit dexamethasone PO

- Clinical Decision Support yellow note updated to: *'Give IV dexamethasone prior to oBINutuzumab infusion if reaction to previous oBINutuzumab was Grade 3, or lymphocyte counts greater than $25 \times 10^9/L$ before Day 1 of current cycle:'*

Give IV dexamethasone prior to oBINutuzumab infusion if reaction to previous oBINutuzumab was Grade 3, or lymphocyte counts greater than $25 \times 10^9/L$ before Day 1 of current cycle:

- Dexamethasone IV: removed 'administer over' time

dexamethasone
20 mg, IV, once oncology, drug form: inj
60 minutes prior to oBINutuzumab. Day 1

- All Clinical Decision Support notes and orders for repeat medications to be given with oBINutuzumab infusion if exceeding 4 hours removed including: Dexamethasone, Acetaminophen PRN range dose, diphenhydramine
- Removed turquoise CDS note "Vital signs prior to start of infusion, at every increment of infusion rate, and as clinically indicated post infusion"
- Order comments for oBINutuzumab Day 1 updated

Details for oBINutuzumab (oBINutuzumab - oncology)

Order comments
If no infusion reaction or only Grade 1 infusion reaction in the previous infusion and final infusion rate 100 mg/h or faster: Start infusion at 100 mg/h for 30 minutes; if tolerated, may escalate rate in increments of 100 mg/h every 30 minutes until rate = 400 mg/h. Refer to protocol appendix for oBINutuzumab infusion rate titration table. Day 1


- **Next cycle labs phase:**
 - Added unselected ALT (in addition to HBV Viral load)

If clinically indicated:

- Alanine Aminotransferase
Blood, once, Order for future visit
- Hepatitis B Viral Load (Rx monitoring)
Blood, once, Order for future visit

- **Scheduling phase:**

- Updated nurse and chair times for Infusion Chemotherapy Visit Day 1




ONCP LY LYGDPO Maintenance Cycles 7 to 18:

- **Chemotherapy phase:**


- Clinical Decision Support note updated to: Give IV dexamethasone prior to oBINutuzumab infusion if reaction to previous oBINutuzumab was Grade 3, or lymphocyte counts greater than $25 \times 10^9/L$ before Day 1 of current cycle:

Give IV dexamethasone prior to oBINutuzumab infusion if reaction to previous oBINutuzumab was Grade 3, or lymphocyte counts greater than $25 \times 10^9/L$ before Day 1 of current cycle:

- Dexamethasone IV: removed 'administer over' time



- All Clinical Decision Support notes and orders for repeat medications to be given with oBINutuzumab infusion if exceeding 4 hours removed including: Dexamethasone, Acetaminophen PRN range dose, diphenhydramine
- Removed turquoise CDS note "Vital signs prior to start of infusion, at every increment of infusion rate, and as clinically indicated post infusion"
- Order comments for oBINutuzumab Day 1 updated




- **Next cycle labs phase:**

- Added unselected ALT (in addition to HBV Viral load)



- **Scheduling phase:**

- Updated nurse and chair times for Infusion Chemotherapy Visit Day 1



Versioning:

Jira: CST-302418


Protocols: LYCVPO

Cycles/PowerPlans:

- ONCP LY LYCVPO Pretreatment Plan
- ONCP LY LYCVPO Induction Cycle 1
- ONCP LY LYCVPO Induction Cycles 2 to 6
- ONCP LY LYCVPO Maintenance Cycles 7 to 18

ONCP LY LYCVPO Pretreatment Plan:


- Updated Clinical Decision Support yellow note to: *“If HBsAg or HBcoreAb positive, start hepatitis B prophylaxis as per SCHBV protocol”*




ONCP LY LYCVPO Induction Cycle 1:

• **Chemotherapy phase:**


- Clinical Decision Support yellow note updated to: *‘Give IV dexamethasone prior to oBINutuzumab infusion if reaction to previous oBINutuzumab was Grade 3, or lymphocyte counts greater than 25 x 10^9/L before Cycle 1 Day 1.’*




- Dexamethasone IV: removed ‘administer over’ time



- All Clinical Decision Support notes and orders for repeat medications to be given with oBINutuzumab infusion if exceeding 4 hours removed including: Dexamethasone, Acetaminophen PRN range dose, diphenhydramine
- Removed turquoise Clinical Decision Support note for vital signs and monitoring for oBINutuzumab
- Removed turquoise Clinical Decision Support note “Days 8 and 15: Vital signs prior to start of infusion, at every increment of infusion rate, and as clinically indicated post infusion”
- Order comments for oBINutuzumab Day 2 updated




- Order comments for oBINutuzumab Days 8 and 15 updated



• **Next cycle labs phase:**

- Added unselected Hepatitis B Viral Load



- **Scheduling phase:**

- Updated nurse and chair times for Infusion Chemotherapy Visit Day 2, 8, and 15

<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/> Infusion Chemotherapy Visit	Within 2 Weeks, Chair Time: 150 minutes, Nurse Time: 90 minutes, ONCP LY LYCVPO Induction Cycle 1 Day 1
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/> Infusion Chemotherapy Visit	Within 2 Weeks, Chair Time: 360 Minutes, Nurse Time: 60 minutes, ONCP LY LYCVPO Induction Cycle 1 Day 2
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/> Infusion Chemotherapy Visit	Within 2 Weeks, Chair Time: 270 minutes, Nurse Time: 60 minutes, ONCP LY LYCVPO Induction Cycle 1 Day 8
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/> Infusion Chemotherapy Visit	Within 2 Weeks, Chair Time: 270 minutes, Nurse Time: 60 minutes, ONCP LY LYCVPO Induction Cycle 1 Day 15

ONCP LY LYCVPO Induction Cycles 2 to 6:

- **Chemotherapy phase:**

- Clinical Decision Support note updated to: 'Give IV dexamethasone prior to oBINutuzumab infusion if reaction to previous oBINutuzumab was Grade 3, or lymphocyte counts greater than $25 \times 10^9/L$ before Day 1 of current cycle.'

Give IV dexamethasone prior to oBINutuzumab infusion if reaction to previous oBINutuzumab was Grade 3, or lymphocyte counts greater than $25 \times 10^9/L$ before Day 1 of current cycle:

- Dexamethasone IV: removed 'administer over' time

dexamethasone

20 mg, IV, once oncology, drug form: inj

60 minutes prior to oBINutuzumab. Day 1

- All Clinical Decision Support notes and orders for repeat medications to be given with oBINutuzumab infusion if exceeding 4 hours removed including: Dexamethasone, Acetaminophen PRN range dose, diphenhydramine
- Removed turquoise CDS note "Vital signs prior to start of infusion, at every increment of infusion rate, and as clinically indicated post infusion"
- Order comments for oBINutuzumab Day 1 updated

Details for oBINutuzumab (oBINutuzumab - oncology)

Order comments

If no infusion reaction or only Grade 1 infusion reaction in the previous infusion and final infusion rate 100 mg/h or faster: Start at 100 mg/h. Increase by 100 mg/h every 30 minutes until rate = 400 mg/h unless toxicity occurs. Refer to protocol appendix for oBINutuzumab infusion rate titration table. Day 1

- **Next cycle labs phase:**

- Added unselected Hepatitis B Viral Load

Hepatitis B Viral Load (Rx monitoring)
Blood, once, Order for future visit

- **Scheduling phase:**


- Updated nurse and chair times for Infusion Chemotherapy Visit Day 1

<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/> Infusion Chemotherapy Visit	Within 2 Weeks, Chair Time: 330 minutes, Nurse Time: 60 minutes, ONCP LY LYCVPO Induction Cycles 2 to 6 Day 1
-------------------------------------	---	---


ONCP LY LYCVPO Maintenance Cycles 7 to 18:

• **Chemotherapy phase:**

- Clinical Decision Support note updated to: 'Give IV dexamethasone prior to oBINutuzumab infusion if reaction to previous oBINutuzumab was Grade 3, or lymphocyte counts greater than $25 \times 10^9/L$ before Day 1 of current cycle:'

Give IV dexamethasone prior to oBINutuzumab infusion if reaction to previous oBINutuzumab was Grade 3, or lymphocyte counts greater than $25 \times 10^9/L$ before Day 1 of current cycle:

- Dexamethasone IV: removed 'administer over' time

dexamethasone
20 mg, IV, once oncology, drug form: inj
60 minutes prior to oBINutuzumab. Day 1

- All Clinical Decision Support notes and orders for repeat medications to be given with oBINutuzumab infusion if exceeding 4 hours removed including: Dexamethasone, Acetaminophen PRN range dose, diphenhydramine
- Removed turquoise CDS note "Vital signs prior to start of infusion, at every increment of infusion rate, and as clinically indicated post infusion"
- Order comments for oBINutuzumab Day 1 updated


▼ Details for oBINutuzumab (oBINutuzumab - oncology)

Details Order Comments

Order comments
If no infusion reaction or only Grade 1 infusion reaction in the previous infusion and final infusion rate 100 mg/h or faster: Start at 100 mg/h. Increase by 100 mg/h every 30 minutes until rate = 400 mg/h unless toxicity occurs. Refer to protocol appendix for oBINutuzumab infusion rate titration table. Day 1


• **Next cycle labs phase:**

- Added unselected Hepatitis B Viral Load

Blood, once, Order for future visit
 Hepatitis B Viral Load (Rx monitoring)
Blood, once, Order for future visit

• **Scheduling phase:**

- Updated nurse and chair times for Infusion Chemotherapy Visit Day 1



Component	Start	End
ONCP LY LYCVPO Maintenance Cycles 7 to 18 - Cycle 7, Scheduling (Initiated Pending)		
<input checked="" type="checkbox"/> Infusion Chemotherapy Visit	Within 2 Weeks, Chair Time: 240 minutes, Nurse Time: 45 minutes,	ONCP LY LYCVPO Maintenance Cycles 7 to 18 Day 1

Versioning:

Jira: CST-302418

Protocols: LYCHOPO

Cycles/PowerPlans:

- ONCP LY LYCHOPO Pretreatment Plan
- ONCP LY LYCHOPO Cyclophosphamide Hyperbilirubinemia Option Cycle 1
- ONCP LY LYCHOPO Cyclophosphamide Hyperbilirubinemia Option Cycles 2 to 6
- ONCP LY LYCHOPO DOXOrubicin Option Cycle 1
- ONCP LY LYCHOPO DOXOrubicin Option Cycles 2 to 6
- ONCP LY LYCHOPO Etoposide Cardiac Dysfunction Option Cycle 1
- ONCP LY LYCHOPO Etoposide Cardiac Dysfunction Option Cycles 2 to 6
- ONCP LY LYCHOPO Maintenance Cycles 7 to 18

ONCP LY LYCHOPO Pretreatment Plan:

- Updated Yellow Clinical Decision Support note to: *“If HBsAg or HBcoreAb positive, start hepatitis B prophylaxis as per SCHBV protocol”*

If HBsAg or HBcoreAb positive, start hepatitis B prophylaxis as per SCHBV protocol

ONCP LY LYCHOPO Cycle 1 (all options):

• **Chemotherapy phase:**

- Clinical Decision Support note updated to: *‘Give IV dexamethasone prior to oBINutuzumab infusion if reaction to previous oBINutuzumab was Grade 3, or lymphocyte counts greater than $25 \times 10^9/L$ before Cycle 1 Day 1.’*

Give IV dexamethasone prior to oBINutuzumab infusion if reaction to previous oBINutuzumab was Grade 3, or lymphocyte counts greater than $25 \times 10^9/L$ before Cycle 1 Day 1:

- Dexamethasone IV: removed ‘administer over’ time and aligned order comments to state “ 60 minutes prior to oBINutuzumab”

Pre-medications for oBINutuzumab:

dexamethasone
20 mg, IV, once oncology, drug form: inj
60 minutes prior to oBINutuzumab. Day 2

- All Clinical Decision Support notes and orders for repeat medications to be given with oBINutuzumab infusion if exceeding 4 hours removed including: Dexamethasone, Acetaminophen PRN range dose, diphenhydramine
- Removed turquoise Clinical Decision Support note for vital signs and monitoring for oBINutuzumab
- Removed turquoise Clinical Decision Support note “Days 8 and 15: Vital signs prior to start of infusion, at every increment of infusion rate, and as clinically indicated post infusion”
- Order comments for oBINutuzumab Day 2 updated

Details for oBINutuzumab (oBINutuzumab - oncology)

Details Order Comments

Order comments

Start infusion at 50 mg/h; after 30 minutes, increase by 50 mg/h every 30 minutes until rate = 400 mg/h unless toxicity occurs. Refer to protocol appendix for oBINutuzumab infusion rate titration table. For first dose, constant visual observation during dose increase and for 30 minutes after infusion completed. Vital signs not required unless symptomatic.

If flushing, dyspnea, rigors, rash, pruritus, vomiting, chest pain, any other new acute discomfort or exacerbation of any existing symptoms occur, stop infusion and page physician. Day 2

- Order comments for oBINutuzumab Days 8 and 15 updated

Details for oBINutuzumab (oBINutuzumab - oncology)

Order comments

If no infusion reaction or only Grade 1 infusion reaction in the previous infusion and final infusion rate 100 mg/h or faster: Start infusion at 100 mg/h for 30 minutes; if tolerated, may escalate rate in increments of 100 mg/h every 30 minutes until rate = 400 mg/h. Refer to protocol appendix for oBINutuzumab infusion rate titration table. Days 8 and 15

- Next cycle labs phase:
 - Added unselected Hepatitis B Viral Load

Hepatitis B Viral Load (Rx monitoring)
Blood, once, Order for future visit

- Scheduling phase:
 - Updated nurse and chair times for Infusion Chemotherapy Visit Day 2, 8, and 15

Component	Status	Dose ...	Details
ONCP LY LYCHOPO DOXOrubicin Option Cycle 1 - Cycle 1, Scheduling (Initiated Pending)			
<input checked="" type="checkbox"/> Infusion Chemotherapy Visit			Within 2 days, Chair Time: 165 minutes, Nurse Time: 105 minutes, ONCP LY LYCHOPO DOXOrubicin Option Cycle 1 Day 1
<input checked="" type="checkbox"/> Infusion Chemotherapy Visit			Within 2 days, Chair Time: 330 minutes, Nurse Time: 60 minutes, ONCP LY LYCHOPO DOXOrubicin Option Cycle 1 Day 2
<input checked="" type="checkbox"/> Infusion Chemotherapy Visit			Within 2 days, Chair Time: 270 minutes, Nurse Time: 60 minutes, ONCP LY LYCHOPO DOXOrubicin Option Cycle 1 Day 8
<input checked="" type="checkbox"/> Infusion Chemotherapy Visit			Within 2 days, Chair Time: 270 minutes, Nurse Time: 60 minutes, ONCP LY LYCHOPO DOXOrubicin Option Cycle 1 Day 15
<input checked="" type="checkbox"/> Follow Up - Clinic - Oncology On Treatment			Physician Specialty: Medical Oncology, Tumor Group: Lymphoma and Melanoma

ONCP LY LYCHOPO Cycle 2 to 6 (all options):

- Chemotherapy phase:
 - Clinical Decision Support note updated to: 'Give IV dexamethasone prior to oBINutuzumab infusion if reaction to previous oBINutuzumab was Grade 3, or lymphocyte counts greater than $25 \times 10^9/L$ before Day 1 of current cycle.'

Give IV dexamethasone prior to oBINutuzumab infusion if reaction to previous oBINutuzumab was Grade 3, or lymphocyte counts greater than $25 \times 10^9/L$ before Day 1 of current cycle:

- Dexamethasone IV: removed 'administer over' time

dexamethasone
20 mg, IV, once oncology, drug form: inj
60 minutes prior to oBINutuzumab. Day 1


- All Clinical Decision Support notes and orders for repeat medications to be given with oBINutuzumab infusion if exceeding 4 hours removed including: Dexamethasone, Acetaminophen PRN range dose, diphenhydramine
- Removed turquoise CDS note "Vital signs prior to start of infusion, at every increment of infusion rate, and as clinically indicated post infusion"
- Order comments for oBINutuzumab Day 1 updated

Details for oBINutuzumab (oBINutuzumab - oncology)

Order comments

If no infusion reaction or only Grade 1 infusion reaction in the previous infusion and final infusion rate 100 mg/h or faster: Start at 100 mg/h. Increase by 100 mg/h every 30 minutes until rate = 400 mg/h unless toxicity occurs. Refer to protocol appendix for oBINutuzumab infusion rate titration table. Day 1

- Next cycle labs phase:
 - Added unselected Hepatitis B Viral Load




ONCP LY LYCHOPO Maintenance Cycles 7 to 18


- Chemotherapy phase:
 - Clinical Decision Support note updated to: *'Give IV dexamethasone prior to oBINutuzumab infusion if reaction to previous oBINutuzumab was Grade 3, or lymphocyte counts greater than $25 \times 10^9/L$ before Day 1 of current cycle.'*

Give IV dexamethasone prior to oBINutuzumab infusion if reaction to previous oBINutuzumab was Grade 3, or lymphocyte counts greater than $25 \times 10^9/L$ before Day 1 of current cycle:

- Dexamethasone IV: removed 'administer over' time




- Updated order comments for acetaminophen and diphenhydramine pre meds to "30 minutes prior to oBINutuzumab"




- All Clinical Decision Support notes and orders for repeat medications to be given with oBINutuzumab infusion if exceeding 4 hours removed including: Dexamethasone, Acetaminophen PRN range dose, diphenhydramine
- Removed turquoise CDS note "Vital signs prior to start of infusion, at every increment of infusion rate, and as clinically indicated post infusion"
- Order comments for oBINutuzumab Day 1 updated


Details for oBINutuzumab (oBINutuzumab - oncology)



- Next cycle labs phase:
 - Added unselected Hepatitis B Viral Load



- **Scheduling phase:**
 - Updated nurse and chair times for Infusion Chemotherapy Visit Day 1



Versioning:

Jira: CST-302418

Protocols: LYVENOB

Cycles/PowerPlans:

- ONCP LY LYVENOB Cycle 1
- ONCP LY LYVENOB Cycle 2 High TLS Risk Ramp-Up Week 2 (Inpatient)
- ONCP LY LYVENOB Cycle 2 Low/Moderate TLS Risk Ramp-Up Weeks 1 to 5
- ONCP LY LYVENOB Post Ramp-up Cycles 3 to 6

ONCP LY LYVENOB Cycle 1:

- **Chemotherapy phase:**
 - Clinical Decision Support note updated to: Give IV dexamethasone prior to oBINutuzumab infusion if reaction to previous oBINutuzumab was Grade 3, or lymphocyte counts greater than $25 \times 10^9/L$ in labs drawn for Day 2 oBINutuzumab:

Give IV dexamethasone prior to oBINutuzumab infusion if reaction to previous oBINutuzumab was Grade 3, or lymphocyte counts greater than $25 \times 10^9/L$ in labs drawn for Day 2 oBINutuzumab:

- Sequenced CDS note and dexamethasone above acetaminophen and diphenhydramine

<input type="checkbox"/>	<p>Give IV dexamethasone prior to oBINutuzumab infusion if reaction to previous oBINutuzumab was Grade 3, or lymphocyte counts greater than $25 \times 10^9/L$ in labs drawn for Day 2 oBINutuzumab:</p> <ul style="list-style-type: none"> • dexamethasone 20 mg, IV, once oncology, drug form: inj 60 minutes prior to oBINutuzumab. Days 8 and 15
<input checked="" type="checkbox"/>	<ul style="list-style-type: none"> • acetaminophen 650 mg, PO, once oncology, drug form: tab, Use Patient Supply 30 minutes prior to oBINutuzumab. Days 1, 2, 8, 15
<input checked="" type="checkbox"/>	<ul style="list-style-type: none"> • diphenhydrAMINE 50 mg, PO, once oncology, drug form: cap, Use Patient Supply 30 minutes prior to oBINutuzumab. Days 1, 2, 8, 15

- Dexamethasone IV: removed 'administer over' time

dexamethasone
20 mg, IV, once oncology, drug form: inj
60 minutes prior to oBINutuzumab. Days 8 and 15

- Updated order comments to acetaminophen and diphenhydramine

acetaminophen
650 mg, PO, once oncology, drug form: tab, Use Patient Supply
30 minutes prior to oBINutuzumab. Days 1, 2, 8, 15

diphenhydrAMINE
50 mg, PO, once oncology, drug form: cap, Use Patient Supply
30 minutes prior to oBINutuzumab. Days 1, 2, 8, 15

- Order comments for oBINutuzumab Day 1 updated

Details for oBINutuzumab (oBINutuzumab - oncology)

Order comments

Administer over 4 hours at 25 mg/h. Refer to protocol appendix for oBINutuzumab infusion rate titration table. Cycle 1 Days 1 and 2: constant visual observation during dose increases and for 30 minutes after infusion completed. Vital signs not required unless symptomatic. Refer to protocol for resuming infusion following a reaction.

If flushing, dyspnea, rigors, rash, pruritus, vomiting, chest pain, any other new acute discomfort or exacerbation of any existing symptoms occur, stop infusion and page physician. Day 1

- Order comments for oBINutuzumab Day 2 updated

Details for oBINutuzumab (oBINutuzumab - oncology)

Order comments

Start at 50 mg/h; after 30 minutes, increase by 50 mg/h every 30 minutes until rate = 400 mg/h unless toxicity occurs. Refer to protocol appendix for oBINutuzumab infusion rate titration table. Cycle 1 Days 1 and 2: constant visual observation during dose increases and for 30 minutes after infusion completed. Vital signs not required unless symptomatic. Refer to protocol for resuming infusion following a reaction.

If flushing, dyspnea, rigors, rash, pruritus, vomiting, chest pain, any other new acute discomfort or exacerbation of any existing symptoms occur, stop infusion and page physician. Day 2

- Order comments for oBINutuzumab Days 8 and 15 updated

Details for oBINutuzumab (oBINutuzumab - oncology)

Order comments

If no infusion reaction or only Grade 1 infusion reaction in the previous infusion and final infusion rate was 100 mg/h or faster: Start at 100 mg/h. Increase by 100 mg/h every 30 minutes until rate = 400 mg/h unless toxicity occurs. Refer to protocol appendix for oBINutuzumab infusion rate titration table. Days 8 and 15

- Scheduling phase:**

- Updated nurse and chair times for Infusion Chemotherapy Visit Day 1, 2, 8, and 15

Component	Status	Use	Details
ONCP LY LYVENOB Cycle 1 - Cycle 1, Scheduling (Initiated Pending)			
Infusion Chemotherapy Visit			Within 2 Weeks, Days 1, 8, 15 chemo must be given on a Thursday for low-medium TLS risk, Chair Time: 360 Minutes, Nurse Time: 90 minutes, ONCP LY LYVENOB Cycle 1 Day 1
Infusion Chemotherapy Visit			Within 2 Weeks, Chair Time: 330 minutes, Nurse Time: 60 minutes, ONCP LY LYVENOB Cycle 1 Day 2
Infusion Chemotherapy Visit			Within 2 Weeks, Days 1, 8, 15 chemo must be given on a Thursday for low-medium TLS risk, Chair Time: 255 minutes, Nurse Time: 45 minutes, ONCP LY LYVENOB Cycle 1 Day 8
Infusion Chemotherapy Visit			Within 2 Weeks, Days 1, 8, 15 chemo must be given on a Thursday for low-medium TLS risk, Chair Time: 255 minutes, Nurse Time: 45 minutes, ONCP LY LYVENOB Cycle 1 Day 15

ONCP LY LYVENOB Cycle 2 High TLS Risk Ramp-Up Week 2 (Inpatient)

- Chemotherapy phase:**

- Clinical Decision Support note updated to: 'Give IV dexamethasone prior to oBINutuzumab infusion if previous reaction was Grade 3, or if lymphocyte count greater than $25 \times 10^9/L$ in labs drawn for Cycle 2 Day 8.'

Give IV dexamethasone prior to oBINutuzumab infusion if previous reaction was Grade 3, or if lymphocyte count greater than $25 \times 10^9/L$ in labs drawn for Cycle 2 Day 8:

- Sequenced CDS note and dexamethasone above acetaminophen and diphenhydramine

Pre-Medications

Give IV dexamethasone prior to oBINutuzumab infusion if previous reaction was Grade 3, or if lymphocyte count greater than $25 \times 10^9/L$ in labs drawn for Cycle 2 Day 8:

- dexamethasone
20 mg, IV, once oncology, drug form: inj
60 minutes prior to oBINutuzumab. Day 1
- acetaminophen
650 mg, PO, once oncology, drug form: tab
30 minutes prior to oBINutuzumab. Day 1
- diphenhydrAMINE
50 mg, PO, once oncology, drug form: cap
30 minutes prior to oBINutuzumab. Day 1

- Dexamethasone IV: removed 'administer over' time

dexamethasone
20 mg, IV, once oncology, drug form: inj
60 minutes prior to oBINutuzumab. Day 1

- Order comments for oBINutuzumab Day 1 updated

Details for oBINutuzumab (oBINutuzumab - oncology)

Order Comments

Order comments
If no infusion reaction or only Grade 1 infusion reaction in the previous infusion and final infusion rate 100 mg/h or faster: Start at 100 mg/h. Increase by 100 mg/h every 30 minutes until rate = 400 mg/h unless toxicity occurs. Refer to protocol appendix for oBINutuzumab infusion rate titration table. Day 1

ONCP LY LYVENOB Cycle 2 Low/Moderate TLS Risk Ramp-Up Weeks 1 to 5

Chemotherapy phase:

- Clinical Decision Support note updated to: 'Give IV dexamethasone prior to oBINutuzumab infusion if previous reaction was Grade 3, or if lymphocyte count greater than 25 x 10⁹/L in labs drawn for Cycle 2 Day 8.'

Give IV dexamethasone prior to oBINutuzumab infusion if previous reaction was Grade 3, or if lymphocyte count greater than 25 x 10⁹/L in labs drawn for Cycle 2 Day 8:

- Sequenced CDS note and dexamethasone above acetaminophen and diphenhydramine

Give IV dexamethasone prior to oBINutuzumab infusion if previous reaction was Grade 3, or if lymphocyte count greater than 25 x 10⁹/L in labs drawn for Cycle 2 Day 8:

- dexamethasone
20 mg, IV, once oncology, drug form: inj
60 minutes prior to oBINutuzumab. Day 8
- acetaminophen
650 mg, PO, once oncology, drug form: tab, Use Patient Supply
30 minutes prior to oBINutuzumab. Day 8
- diphenhydrAMINE
50 mg, PO, once oncology, drug form: cap, Use Patient Supply
30 minutes prior to oBINutuzumab. Day 8

- Dexamethasone IV: removed 'administer over' time

dexamethasone
20 mg, IV, once oncology, drug form: inj
60 minutes prior to oBINutuzumab. Day 8

- Order comments for oBINutuzumab Day 8 updated

Details for oBINutuzumab (oBINutuzumab - oncology)

Order Comments

Order comments
If no infusion reaction or only Grade 1 infusion reaction in the previous infusion and final infusion rate 100 mg/h or faster: Start at 100 mg/h. Increase by 100 mg/h every 30 minutes until rate = 400 mg/h unless toxicity occurs. Refer to protocol appendix for oBINutuzumab infusion rate titration table. Day 8

Scheduling phase:

- Updated nurse and chair times for Infusion Chemotherapy Visit Day 8

Component	Status	Dose	Details
ONCP LY LYVENOB Cycle 2 Low/Moderate TLS Risk Ramp-Up Weeks 1 to 5 - Cycle 2, Scheduling (Initiated Pending)			
Infusion Chemotherapy Visit	Within 2 Weeks, Day 8 must be on a Thursday	Chair Time: 240 minutes, Nurse Time: 45 minutes	ONCP LY LYVENOB Cycle 2 Low/Moderate TLS Risk Ramp-Up Weeks Day 8

ONCP LY LYVENOB Post Ramp-up Cycles 3 to 6

Chemotherapy phase:

- Clinical Decision Support note updated to: 'Give IV dexamethasone prior to oBINutuzumab infusion if reaction to previous oBINutuzumab was Grade 3, or lymphocyte counts greater than 25 x 10⁹/L before Day 1 of current cycle.'

Give IV dexamethasone prior to oBINutuzumab infusion if reaction to previous oBINutuzumab was Grade 3, or lymphocyte counts greater than 25 x 10⁹/L before Day 1 of current cycle:

- Sequenced CDS note and dexamethasone above acetaminophen and diphenhydramine

Give IV dexamethasone prior to oBINutuzumab infusion if reaction to previous oBINutuzumab was Grade 3, or lymphocyte counts greater than $25 \times 10^9/L$ before Day 1 of current cycle:

- dexamethasone
20 mg, IV, once oncology, drug form: inj
60 minutes prior to oBINutuzumab. Day 1
- acetaminophen
650 mg, PO, once oncology, drug form: tab, Use Patient Supply
30 minutes prior to oBINutuzumab. Day 1
- diphenhydrAMINE
50 mg, PO, once oncology, drug form: cap, Use Patient Supply
30 minutes prior to oBINutuzumab. Day 1

- Dexamethasone IV: removed 'administer over' time

dexamethasone
20 mg, IV, once oncology, drug form: inj
60 minutes prior to oBINutuzumab. Day 1

- Order comments for acetaminophen and diphenhydramine and dexamethasone changed to "30 minutes prior to oBINutuzumab"

acetaminophen
650 mg, PO, once oncology, drug form: tab, Use Patient Supply
30 minutes prior to oBINutuzumab. Day 1

diphenhydrAMINE
50 mg, PO, once oncology, drug form: cap, Use Patient Supply
30 minutes prior to oBINutuzumab. Day 1

- Order comments for oBINutuzumab Day 1 updated

Details for oBINutuzumab (oBINutuzumab - oncology)

Order Comments

Order comments
If no infusion reaction or only Grade 1 infusion reaction in the previous infusion and final infusion rate 100 mg/h or faster: Start at 100 mg/h. Increase by 100 mg/h every 30 minutes until rate = 400 mg/h unless toxicity occurs. Refer to protocol appendix for oBINutuzumab infusion rate titration table. Day 1

Scheduling phase:

- Updated nurse and chair times for Infusion Chemotherapy Visit Day 1

Infusion Chemotherapy Visit Within 2 Weeks, Day 1 Chair Time: 240 minutes, Nurse Time: 45 minutes, ONCP LY LYVENOB Post Ramp-up Cycles 3 to 6

Versioning:

Jira: CST-302418

Protocols: LYOBCHLOR

Cycles/PowerPlans:

- ONCP LY LYOBCHLOR Pretreatment Plan
- ONCP LY LYOBCHLOR Cycle 1
- ONCP LY LYOBCHLOR Cycles 2+

ONCP LY LYGDPO Pretreatment Plan:


- Updated Yellow Clinical Decision Support note to: "If HBsAg or HBcoreAb positive, start hepatitis B prophylaxis as per SCHBV protocol"

If HBsAg or HBcoreAb positive, follow hepatitis B prophylaxis as per SCHBV protocol


ONCP LY LYOBCHLOR Cycle 1

- **Chemotherapy phase:**


- Clinical Decision Support note updated to: Give IV dexamethasone prior to oBINutuzumab infusion if reaction to previous oBINutuzumab was Grade 3, or lymphocyte counts greater than $25 \times 10^9/L$ before Cycle 1:


 Give IV dexamethasone prior to oBINutuzumab infusion if reaction to previous oBINutuzumab was Grade 3, or lymphocyte counts greater than $25 \times 10^9/L$ before Cycle 1:

- Dexamethasone IV: removed 'administer over' time and added to order comments "60 minutes prior to oBINutuzumab."


 dexamethasone
20 mg, IV, once oncology, drug form: inj
60 minutes prior to oBINutuzumab. Days 8 and 15


- Updated order comments to acetaminophen and diphenhydramine


 acetaminophen
650 mg, PO, once oncology, drug form: tab, Use Patient Supply
30 minutes prior to oBINutuzumab. Days 1, 2, 8, 15


 diphenhydrAMINE
50 mg, PO, once oncology, drug form: cap, Use Patient Supply
30 minutes prior to oBINutuzumab. Days 1, 2, 8, 15

- Sequenced CDS note and dexamethasone above acetaminophen and diphenhydramine

 Give IV dexamethasone prior to oBINutuzumab infusion if reaction to previous oBINutuzumab was Grade 3, or lymphocyte counts greater than $25 \times 10^9/L$ before Cycle 1:

 dexamethasone
20 mg, IV, once oncology, drug form: inj
60 minutes prior to oBINutuzumab. Days 8 and 15

 acetaminophen
650 mg, PO, once oncology, drug form: tab, Use Patient Supply
30 minutes prior to oBINutuzumab. Days 1, 2, 8, 15

 diphenhydrAMINE
50 mg, PO, once oncology, drug form: cap, Use Patient Supply
30 minutes prior to oBINutuzumab. Days 1, 2, 8, 15

- Removed turquoise CDS note for vital signs and monitoring for oBINutuzumab
- Order comments for oBINutuzumab Day 1 updated

Details for oBINutuzumab (oBINutuzumab - oncology)

Order comments
Administer over 4 hours at 25 mg/h. Refer to protocol appendix for oBINutuzumab infusion rate titration table. Cycle 1 Days 1 and 2: constant visual observation during dose increases and for 30 minutes after infusion completed. Vital signs not required unless symptomatic.
If flushing, dyspnea, rigors, rash, pruritus, vomiting, chest pain, any other new acute discomfort or exacerbation of any existing symptoms occur, stop infusion and page physician. Day 1

- Order comments for oBINutuzumab Day 2 updated

Details for oBINutuzumab (oBINutuzumab - oncology)

Order comments
Start at 50 mg/h; after 30 minutes, increase by 50 mg/h every 30 minutes until rate = 400 mg/h unless toxicity occurs. Refer to protocol appendix for oBINutuzumab infusion rate titration table.
Cycle 1 Days 1 and 2: constant visual observation during dose increases and for 30 minutes after infusion completed. Vital signs not required unless symptomatic.
If flushing, dyspnea, rigors, rash, pruritus, vomiting, chest pain, any other new acute discomfort or exacerbation of any existing symptoms occur, stop infusion and page physician. Day 2

- Order comments for oBINutuzumab Days 8 and 15 updated

▼ Details for **oBINutuzumab (oBINutuzumab - oncology)**

Details Order Comments

Order comments

If no infusion reaction or only Grade 1 infusion reaction in the previous infusion and final infusion rate was 100 mg/h or faster: Start at 100 mg/h. Increase by 100 mg/h every 30 minutes until rate = 400 mg/h unless toxicity occurs. Refer to protocol appendix for oBINutuzumab infusion rate titration table. Days 8 and 15

- Next cycle labs phase:

- Added unselected ALT (in addition to HBV Viral load)

<input type="checkbox"/>	<input checked="" type="checkbox"/>	Alanine Aminotransferase	Blood, once, Order for future visit
<input type="checkbox"/>	<input checked="" type="checkbox"/>	Hepatitis B Viral Load (Rx monitoring)	Blood, once, Order for future visit

- Scheduling phase:

- Updated nurse and chair times for Infusion Chemotherapy Visit Day 1, 2, 8, and 15

ONCP LY LYOBCHLOR Cycle 1 - Cycle 1, Scheduling (Initiated Pending)			
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	Infusion Chemotherapy Visit	Within 2 Weeks, Chair Time: 345 minutes, Nurse Time: 75 minutes, ONCP LY LYOBCHLOR Cycle 1 Day 1
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	Infusion Chemotherapy Visit	Within 2 Weeks, Chair Time: 330 minutes, Nurse Time: 60 minutes, ONCP LY LYOBCHLOR Cycle 1 Day 2
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	Infusion Chemotherapy Visit	Within 2 Weeks, Chair Time: 240 minutes, Nurse Time: 45 minutes, ONCP LY LYOBCHLOR Cycle 1 Day 8
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	Infusion Chemotherapy Visit	Within 2 Weeks, Chair Time: 240 minutes, Nurse Time: 45 minutes, ONCP LY LYOBCHLOR Cycle 1 Day 15

ONCP LY LYOBCHLOR Cycles 2+

- Chemotherapy phase:

- Clinical Decision Support note updated to: 'Give IV dexamethasone prior to oBINutuzumab infusion if reaction to previous oBINutuzumab was Grade 3, or lymphocyte counts greater than $25 \times 10^9/L$ before Day 1 of current cycle.'

Give IV dexamethasone prior to oBINutuzumab infusion if reaction to previous oBINutuzumab was Grade 3, or lymphocyte counts greater than $25 \times 10^9/L$ before Day 1 of current cycle:

- Dexamethasone IV: removed 'administer over' time and added to order comments "60 minutes prior to oBINutuzumab."

dexamethasone
20 mg, IV, once oncology, drug form: inj
60 minutes prior to oBINutuzumab. Day 1

- Updated order comments to acetaminophen and diphenhydramine

<input checked="" type="checkbox"/>		acetaminophen	650 mg, PO, once oncology, drug form: tab, Use Patient Supply 30 minutes prior to oBINutuzumab. Day 1
<input checked="" type="checkbox"/>		diphenhydrAMINE	50 mg, PO, once oncology, drug form: cap, Use Patient Supply 30 minutes prior to oBINutuzumab. Day 1

- Sequenced CDS note and dexamethasone above acetaminophen and diphenhydramine

Give IV dexamethasone prior to oBINutuzumab infusion if reaction to previous oBINutuzumab was Grade 3, or lymphocyte counts greater than $25 \times 10^9/L$ before Day 1 of current cycle:

- dexamethasone
20 mg, IV, once oncology, drug form: inj
60 minutes prior to oBINutuzumab. Day 1
- acetaminophen
650 mg, PO, once oncology, drug form: tab, Use Patient Supply
30 minutes prior to oBINutuzumab. Day 1
- diphenhydrAMINE
50 mg, PO, once oncology, drug form: cap, Use Patient Supply
30 minutes prior to oBINutuzumab. Day 1

- Order comments for oBINutuzumab Day 1 updated

Details for oBINutuzumab (oBINutuzumab - oncology)

Order comments

If no infusion reaction or only Grade 1 infusion reaction in the previous infusion and final infusion rate 100 mg/h or faster: Start at 100 mg/h. Increase by 100 mg/h every 30 minutes until rate = 400 mg/h unless toxicity occurs. Refer to protocol appendix for oBINutuzumab infusion rate titration table. Day 1

- Next cycle labs phase:

- Added unselected ALT (in addition to HBV Viral load)

- Alanine Aminotransferase
Blood, once, Order for future visit
- Hepatitis B Viral Load (Rx monitoring)
Blood, once, Order for future visit

- Scheduling phase:

- Updated nurse and chair times for Infusion Chemotherapy Visit Day 1

Infusion Chemotherapy Visit Within 2 Weeks, Chair Time: 240 minutes, Nurse Time: 45 minutes, ONCP LY LYOBCHLOR Cycles 2+ Day 1

Versioning:

Jira: CST-302418

Protocols: LYBENDO

Cycles/PowerPlans:

- ONCP LY LYBENDO Pretreatment Plan
- ONCP LY LYBENDO Cycle 1
- ONCP LY LYBENDO Cycles 2 to 6
- ONCP LY LYBENDO Cycles 7 to 18

ONCP LY LYBENDO Pretreatment Plan:

- Updated Yellow Clinical Decision Support note to: "If HBsAg or HBcoreAb positive, start hepatitis B prophylaxis as per SCHBV protocol"

If HBsAg or HBcoreAb positive, follow hepatitis B prophylaxis as per SCHBV protocol

ONCP LY LYBENDO Cycle 1

• **Chemotherapy phase:**

- Protocol description updated to: Treatment of riTUXimab-refractory Follicular Lymphoma with bendamustine in combination with oBINutuzumab

[Link to Protocol: Treatment of riTUXimab-refractory Follicular Lymphoma with bendamustine in combination with oBINutuzumab](#)

- Pre-medications for bendamustine sequenced first and all order comments for pre-meds for bendamustine updated

Pre-Medications	
	Patient to take own supply of pre-medications. RN/Pharmacist to confirm
	Pre-medications for bendamustine:
<input checked="" type="checkbox"/>	ondansetron 8 mg, PO, once oncology, drug form: tab, Use Patient Supply Between 30 and 60 minutes prior to bendamustine. Days 1 and 2
<input checked="" type="checkbox"/>	dexamethasone 20 mg, IV, once oncology, drug form: inj 30 minutes prior to bendamustine. Day 1
<input checked="" type="checkbox"/>	dexamethasone ▾ 8 mg, PO, once oncology, drug form: tab, Use Patient Supply Between 30 and 60 minutes prior to bendamustine. Day 2

- Clinical Decision Support note updated to “Give IV dexamethasone prior to oBINutuzumab infusion if reaction to previous oBINutuzumab was Grade 3, or lymphocyte count greater than $25 \times 10^9/L$ before Cycle 1 Day 1.”

Give IV dexamethasone prior to oBINutuzumab infusion if reaction to previous oBINutuzumab was Grade 3, or lymphocyte count greater than $25 \times 10^9/L$ before Cycle 1 Day 1:

- Changed offsets to bendamustine and oBINutuzumab pre-medications as now bendamustine is administered first

Component	Day 1	Day 2
	Future Pending *Est. 26-Feb-2025 08:...	Future Pending *Est. 27-Feb-2025 08:...
Pre-Medications		
Patient to take own supply of pre-medications. RN/Pharmacist to confirm		
Pre-medications for bendamustine:		
<input checked="" type="checkbox"/> ondansetron 8 mg, PO, once oncology, drug form: tab, Use Patient Supply Between 30 and 60 minutes prior to bendamustine. Days 1 and 2	-30 min Planned	-30 min Planned
<input checked="" type="checkbox"/> dexamethasone 20 mg, IV, once oncology, drug form: inj 30 minutes prior to bendamustine. Day 1	-30 min Planned	
<input checked="" type="checkbox"/> dexamethasone ▾ 8 mg, PO, once oncology, drug form: tab, Use Patient Supply Between 30 and 60 minutes prior to bendamustine. Day 2		-30 min Planned

Component	Day 1	Day 2	Day 8	Day 15
	Future Pending *Est. 26-Feb-2025 08:...	Future Pending *Est. 27-Feb-2025 08:...	Future Pending *Est. 05-Mar-2025 08:...	Future Pending *Est. 12-Mar-2025 08:...
Pre-medications for oBINutuzumab:				
Give IV dexamethasone prior to oBINutuzumab infusion if reaction to previous oBINutuzumab was Grade 3, or lymphocyte count greater than $25 \times 10^9/L$ before Cycle 1 Day 1:				
<input checked="" type="checkbox"/> dexamethasone 20 mg, IV, once oncology, drug form: inj 60 minutes prior to oBINutuzumab. Days 8 and 15			-60 min	-60 min
<input checked="" type="checkbox"/> acetaminophen ▾ 650 mg, PO, once oncology, drug form: tab, Use Patient Supply 30 minutes prior to oBINutuzumab. Days 1, 8, 15	+30 min Planned		-30 min	-30 min
<input checked="" type="checkbox"/> diphenhydrAMINE 50 mg, PO, once oncology, drug form: cap, Use Patient Supply 30 minutes prior to oBINutuzumab. Days 1, 8, 15	+30 min Planned		-30 min	-30 min

- **Changed sequence of treatment regimen so bendamustine goes first**

ONCP LY LYBENDO Cycle 1 - Cycle 1, Chemotherapy (Day 1 to 2, 8, 15) (Future Pending) *Est. 26-Feb-2025 08:00 PST - 28 Days				
Component	Day 1	Day 2	Day 8	Day 15
Future Pending	Future Pending	Future Pending	Future Pending	Future Pending
*Est. 26-Feb-2025 08:00 PST	*Est. 27-Feb-2025 08:00 PST	*Est. 05-Mar-2025 08:00 PST	*Est. 12-Mar-2025 08:00 PST	
Actions	Actions	Actions	Actions	Actions
Planned	Planned	Planned	Planned	Planned
0 hr	0 hr	0 hr	0 hr	0 hr
Planned	Planned	Planned	Planned	Planned
0 min	0 min			
Planned	Planned			
+60 min				
Planned			0 min	0 min
Planned			Planned	Planned

- **Dexamethasone IV: removed 'administer over' time**

dexamethasone
 20 mg, IV, once oncology, drug form: inj
 60 minutes prior to oBINutuzumab, Days 8 and 15

- All Clinical Decision Support notes and orders for repeat medications to be given with oBINutuzumab infusion if exceeding 4 hours removed including: Dexamethasone, Acetaminophen PRN range dose, diphenhydramine
- Removed turquoise CDS note "Day 1: For first dose, constant visual observation during dose increases and for 30 minutes after infusion completed. Vital signs not required unless symptomatic"
- Removed turquoise CDS note "Days 8 and 15: Vital signs prior to start of infusion, at every increment of infusion rate, and as clinically indicated post infusion"
- Order comments for oBINutuzumab Day 1 updated

Details for oBINutuzumab (oBINutuzumab - oncology)

Order comments
 Start infusion at 50 mg/h after 30 minutes, increase by 50 mg/h every 30 minutes until rate = 400 mg/h unless toxicity occurs. Refer to protocol appendix for oBINutuzumab infusion rate titration table. For first dose, constant visual observation during dose increases and for 30 minutes after infusion completed. Vital signs not required unless symptomatic.
 If flushing, dyspnea, rigors, rash, pruritus, vomiting, chest pain, any other new acute discomfort or exacerbation of any existing symptoms occur, stop infusion and page physician. Day 1

- **Order comments for oBINutuzumab Days 8 and 15 updated**

Details for oBINutuzumab (oBINutuzumab - oncology)

Order comments
 If no infusion reaction or only Grade 1 infusion reaction in the previous infusion and final infusion rate 100 mg/h or faster: Start infusion at 100 mg/h for 30 minutes; if tolerated, may escalate rate in increments of 100 mg/h every 30 minutes until rate = 400 mg/h. Refer to protocol appendix for oBINutuzumab infusion rate titration table. Days 8 and 15

- **Next cycle labs phase:**
 - Added unselected HBV Viral load

Hepatitis B Viral Load (Rx monitoring)
 Blood, Urine, Order for future visit

- **Scheduling phase:**
 - Updated nurse and chair times for Infusion Chemotherapy Visit Day 1, 2, 8, and 15

ONCP LY LYBENDO Cycle 1 - Cycle 1, Scheduling (Initiated Pending)			
Infusion Chemotherapy Visit	Within 2 Weeks, Day 1	Chair Time: 450 Minutes, Nurse Time: 75 minutes	ONCP LY LYBENDO Cycle 1
Infusion Chemotherapy Visit	Within 2 Weeks, Day 2	Chair Time: 105 minutes, Nurse Time: 45 minutes	ONCP LY LYBENDO Cycle 1
Infusion Chemotherapy Visit	Within 2 Weeks, Day 8	Chair Time: 240 minutes, Nurse Time: 60 minutes	ONCP LY LYBENDO Cycle 1
Infusion Chemotherapy Visit	Within 2 Weeks, Day 15	Chair Time: 240 minutes, Nurse Time: 60 minutes	ONCP LY LYBENDO Cycle 1

ONCP LY LYBENDO Cycles 2 to 6

Chemotherapy phase:

- Protocol description updated to: Treatment of ritUXimab-refractory Follicular Lymphoma with bendamustine in combination with oBINutuzumab

Link to Protocol: Treatment of ritUXimab-refractory Follicular Lymphoma with bendamustine in combination with oBINutuzumab

- Pre-medications for bendamustine sequenced first and all order comments for pre-meds for bendamustine updated

Pre-Medications		Day 1	Day 2
Patient to take own supply of pre-medications. RN/Pharmacist to confirm			
Pre-medications for bendamustine:			
<input checked="" type="checkbox"/>	ondansetron 8 mg, PO, once oncology, drug form: tab, Use Patient Supply Between 30 and 60 minutes prior to bendamustine. Days 1 and 2	-30 min Planned	-30 min Planned
If dexamethasone IV has been given the same day for the oBINutuzumab premedication, then omit dexamethasone PO			
<input checked="" type="checkbox"/>	dexamethasone 8 mg, PO, once oncology, drug form: tab, Use Patient Supply Between 30 and 60 minutes prior to bendamustine. Days 1 and 2	-30 min Planned	-30 min Planned

- Changed offsets to bendamustine and oBINutuzumab pre-medications as now bendamustine is administered first

Component	Day 1	Day 2	
Platelet Count Greater Than or Equal to $80 \times 10^9/L$ within 96 hours	Future Pending *Est. 26-Feb-2025 08:...	Future Pending *Est. 27-Feb-2025 08:...	
Pre-Medications			
Patient to take own supply of pre-medications. RN/Pharmacist to confirm			
Pre-medications for bendamustine:			
<input checked="" type="checkbox"/>	ondansetron 8 mg, PO, once oncology, drug form: tab, Use Patient Supply Between 30 and 60 minutes prior to bendamustine. Days 1 and 2	-30 min Planned	-30 min Planned
If dexamethasone IV has been given the same day for the oBINutuzumab premedication, then omit dexamethasone PO			
<input checked="" type="checkbox"/>	dexamethasone 8 mg, PO, once oncology, drug form: tab, Use Patient Supply Between 30 and 60 minutes prior to bendamustine. Days 1 and 2	-30 min Planned	-30 min Planned

Component	Day 1	Day 2	
Pre-medications for oBINutuzumab:	Future Pending *Est. 26-Feb-2025 08:...	Future Pending *Est. 27-Feb-2025 08:...	
Give IV dexamethasone 30 minutes prior to bendamustine, if reaction to previous oBINutuzumab was Grade 3, or if lymphocyte count greater than $25 \times 10^9/L$ before Day 1 of current cycle:			
<input checked="" type="checkbox"/>	dexamethasone 20 mg, IV, once oncology, drug form: inj 30 minutes prior to bendamustine. Day 1	-30 min Planned	
<input checked="" type="checkbox"/>	acetaminophen 650 mg, PO, once oncology, drug form: tab, Use Patient Supply 30 minutes prior to oBINutuzumab (give during bendamustine infusion). Day 1	+30 min Planned	
<input checked="" type="checkbox"/>	diphenhydrAMINE 50 mg, PO, once oncology, drug form: cap, Use Patient Supply 30 minutes prior to oBINutuzumab (give during bendamustine infusion). Day 1	+30 min Planned	


- Clinical Decision Support note added: 'If dexamethasone IV has been given the same day for the oBINutuzumab premedication, then omit dexamethasone PO' (above dexamethasone PO order)

If dexamethasone IV has been given the same day for the oBINutuzumab premedication, then omit dexamethasone PO

- Clinical Decision Support note updated to "Give IV dexamethasone 30 minutes prior to bendamustine, if reaction to previous oBINutuzumab was Grade 3, or if lymphocyte count greater than $25 \times 10^9/L$ before Day 1 of current cycle"

Give IV dexamethasone 30 minutes prior to bendamustine, if reaction to previous oBINutuzumab was Grade 3, or if lymphocyte count greater than $25 \times 10^9/L$ before Day 1 of current cycle:

- Dexamethasone IV: removed 'administer over' time


 dexamethasone
20 mg, IV, once oncology, drug form: inj
60 minutes prior to oBINutuzumab. Days 8 and 15

- All Clinical Decision Support notes and orders for repeat medications to be given with oBINutuzumab infusion if exceeding 4 hours removed including: Dexamethasone, Acetaminophen PRN range dose, diphenhydramine
- Removed turquoise CDS note "Vital signs prior to start of infusion, and as clinically indicated during and post infusion"
- Changed sequence of treatment regimen so bendamustine goes first

ONCP LYBENDO Cycles 2 to 6 - Cycle 2, Chemotherapy (Day 1 to 2) (Future Pending) *Est. 26-Feb-2025 08:00 PST - 28 Days

		Day 1	Day 2
	Component	Future Pending *Est. 26-Feb-2025 08:...	Future Pending *Est. 27-Feb-2025 08:...
		Actions	Actions
<input checked="" type="checkbox"/>	salbutamol 5 mg, nebulized, q20min, PRN shortness of breath or wheezing, order duration: 3 doses o...	Planned	Planned
	Treatment Regimen		
<input checked="" type="checkbox"/>	Zero Time	0 hr Planned	0 hr Planned
<input checked="" type="checkbox"/>	bendamustine (bendamustine - oncology) 90 mg/m2, IV, once oncology, administer over: 60 minute, drug form: bag Days 1 and 2	0 min Planned	0 min Planned
<input checked="" type="checkbox"/>	oBINutuzumab (oBINutuzumab - oncology) 1,000 mg, IV, once oncology, drug form: bag If no infusion reaction or only Grade 1 infusion reaction in the previous infusion and final ...	+60 min Planned	

- Order comments for bendamustine updated

 bendamustine (bendamustine - oncology)
90 mg/m2, IV, once oncology, administer over: 60 minute, drug form: bag
Days 1 and 2

- Order comments for oBINutuzumab Day 1 updated

Details for oBINutuzumab (oBINutuzumab - oncology)

Order comments
If no infusion reaction or only Grade 1 infusion reaction in the previous infusion and final infusion rate 100 mg/h or faster: Start at 100 mg/h. Increase by 100 mg/h every 30 minutes until rate = 400 mg/h unless toxicity occurs. Refer to protocol appendix for oBINutuzumab infusion rate titration table. Day 1

- Next cycle labs phase:
 - Added unselected HBV Viral load


Hepatitis B Viral Load (Rx monitoring)
Blood, Urine, Order for future visit

- Scheduling phase:
 - Updated nurse and chair times for Infusion Chemotherapy Visit Day 1 and 2

	Component	Status	Dose ...	Details
<input checked="" type="checkbox"/>	ONCP LYBENDO Cycles 2 to 6 - Cycle 2, Scheduling (Initiated Pending)			
<input checked="" type="checkbox"/>	Infusion Chemotherapy Visit			Within 2 Weeks, Chair Time: 315 minutes, Nurse Time: 45 minutes, ONCP LYBENDO Cycles 2 to 6 Day 1
<input checked="" type="checkbox"/>	Infusion Chemotherapy Visit			Within 2 Weeks, Chair Time: 105 minutes, Nurse Time: 45 minutes, ONCP LYBENDO Cycles 2 to 6 Day 2

ONCP LY LYBENDO Cycles 7 to 18

- Chemotherapy phase:
 - Protocol description updated to: Treatment of ritUXimab-refractory Follicular Lymphoma with bendamustine in combination with oBINutuzumab

 Link to Protocol: Treatment of ritUXimab-refractory Follicular Lymphoma with bendamustine in combination with oBINutuzumab

- Resequenced so Clinical Decision Support note and dexamethasone IV orders above acetaminophen and diphenhydramine

- Clinical Decision Support note updated to: “Give IV dexamethasone prior to oBINutuzumab infusion if reaction to previous oBINutuzumab was Grade 3, or if lymphocyte count greater than 25 x 10⁹/L before Day 1 of current cycle:”

- All Clinical Decision Support notes and orders for repeat medications to be given with oBINutuzumab infusion if exceeding 4 hours removed including: Dexamethasone, Acetaminophen PRN range dose, diphenhydramine
- Removed turquoise CDS note “Vital signs prior to start of infusion, and as clinically indicated during and post infusion”
- Order comments for oBINutuzumab Day 1 updated

- Next cycle labs phase:
 - Added unselected HBV Viral load

- Scheduling phase:
 - Updated nurse and chair times for Infusion Chemotherapy Visit Day 1

Versioning:

Jira: CST-302418

Net New Protocols: ULYOGLOFIT, UGUPAVNABI, GIAVPEMPG

ONC LY ULYOGLOFIT (Inpatient)

ONC LY ULYOGLOFIT (Outpatient)

- ONCP LY ULYOGLOFIT Pretreatment Labs
- ONCP LY ULYOGLOFIT (Outpatient) Cycle 1 Day 1
- ONCP LY ULYOGLOFIT (Outpatient) Cycle 2
- ONCP LY ULYOGLOFIT (Outpatient) Cycle 3
- ONCP LY ULYOGLOFIT (Outpatient) Cycle 4+
- ONCP LY ULYOGLOFIT (Inpatient) Cycle 1 Day 8
- ONCP LY ULYOGLOFIT (Inpatient) Cycle 1 Day 15
- ONCP LY ULYOGLOFIT (Inpatient) Cycle 2
- ONCP LY ULYOGLOFIT (Inpatient) Cycle 3
- ONCP LY ULYOGLOFIT (Inpatient) Cycle 4+
- ONCP LY ULYOGLOFIT (Inpatient) Cycle 1 Day 8

ONC GU UGUPAVNABI

- ONCP GU UGUPAVNABI Pretreatment Plan
- ONCP GU UGUPAVNABI Cycles 1 to 3
- ONCP GU UGUPAVNABI Cycles 4+

ONC GI GIAVPEMPG CISplatin Option Cycles 1 to 8

ONC GI GIAVPEMPG CARBOplatin Option Cycles 1 to 8

ONC GI GIAVPEMPG Maintenance Gemcitabine and Pembrolizumab Option Cycles 9+

ONC GI GIAVPEMPG Maintenance Pembrolizumab Only Option Cycles 9+

- ONCP GI GIAVPEMPG Pretreatment Plan
- ONCP GI GIAVPEMPG CISplatin Option Cycles 1 to 8
- ONCP GI GIAVPEMPG CARBOplatin Option Cycles 1 to 8
- ONCP GI GIAVPEMPG Maintenance Gemcitabine and Pembrolizumab Option Cycles 9+
- ONCP GI GIAVPEMPG Maintenance Pembrolizumab Only Option Cycles 9+

Jira: CST-301253, CST-303661, CST-302307

Jira Ticket #

CST-305678, CST-305459, CST-305458, CST-305436, CST-303762, CST-303761, CST-302418, CST-302330, CST-301253, CST-303661, CST-302307

How-to questions?

<http://cstcernerhelp.healthcarebc.ca>

Provincial Digital Health and Information Services

Partnering with the BC health sector, providers and citizens

Need further support?

CST Phone Support: 1-844-214-7444